Euglycaemic glucose clamp: what it can and cannot do, and how to do it

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation

(2016) L. Monnier et al.   DIABETES & METABOLISM

Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?: Table 1

(2015) Philip Home   DIABETES CARE

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

(2015) Helle Linnebjerg et al.   DIABETES CARE

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

(2015) Francesca Porcellati et al.   DIABETES CARE

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

(2015) R. H. A. Becker et al.   DIABETES OBESITY & METABOLISM

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

(2015) T. Heise et al.   DIABETES OBESITY & METABOLISM

The past, present, and future of basal insulins

(2015) Jeremy Pettus et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes

(2014) Francesca Porcellati et al.   DIABETES CARE

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

(2014) M. Shiramoto et al.   DIABETES OBESITY & METABOLISM

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

(2014) A. Steinstraesser et al.   DIABETES OBESITY & METABOLISM

Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification

(2013) Béatrice Heurtault et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes

(2013) L. Meneghini et al.   DIABETES OBESITY & METABOLISM

Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes

(2013) G. Koehler et al.   DIABETES OBESITY & METABOLISM

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus

(2013) S. Korsatko et al.   DRUGS & AGING

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Insulin aspart has a shorter duration of action than human insulin over a wide dose-range

(2012) L. Nosek et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study

(2011) P. Lucidi et al.   DIABETES CARE

The Effects of Anti-insulin Antibodies and Cross-reactivity with Human Recombinant Insulin Analogues in the E170 Insulin Immunometric Assay

(2011) Serim Kim et al.   Korean Journal of Laboratory Medicine

Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes

(2010) S M Ocheltree et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Insulin Glulisine Has a Faster Onset of Action Compared with Insulin Aspart in Healthy Volunteers

(2010) S. Arnolds et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis

(2008) M. Monami et al.   DIABETES OBESITY & METABOLISM

The Pharmacokinetic and Pharmacodynamic Properties of Different Formulations of Biphasic Insulin Aspart: A Randomized, Glucose Clamp, Crossover Study

(2008) T. Heise et al.   Diabetes Technology & Therapeutics

The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back

(2008) S. G. H. A. Swinnen et al.   DIABETOLOGIA

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETOLOGIA